Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
Study Results
Related Studies
Somatropin Treatment to Final Height in Turner Syndrome (GDCT)
This study has been completed.
Study NCT00191113 Information provided by Eli Lilly and Company
First Received on September 12, 2005. Last Updated on December 13, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Turner Syndrome
Additional conditions recognized in this trial
Gonadal Dysgenesis
Primary Ovarian Insufficiency
More general conditions related to this trial
Adnexal Diseases
Cardiovascular Abnormalities
Cardiovascular Diseases
Chromosome Disorders
Congenital Abnormalities
Disorders of Sex Development
Endocrine System Diseases
Genetic Diseases, Inborn
Genital Diseases, Female
Gonadal Disorders
Heart Defects, Congenital
Heart Diseases
Ovarian Diseases
Sex Chromosome Disorders
Sex Chromosome Disorders of Sex Development
Urogenital Abnormalities
Interventions listed in this trial
Somatropin
Ethinyl estradiol
Medroxyprogesterone acetate
Additional drug interventions recognized in this trial
Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Estradiol valerate
Hormones
Medroxyprogesterone
Polyestradiol phosphate
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Contraceptive Agents
Contraceptive Agents, Female
Contraceptive Agents, Male
Contraceptives, Oral
Contraceptives, Oral, Synthetic
Estrogens
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses
Sponsors listed in this trial
Eli Lilly and Company
Back to top of Main Content
